Company Description

Akrivea Bio is developing the first of its kind PSMA-targeted peptidomimetic for diagnostic imaging and radionuclide treatment of prostate cancer with a novel linker region that reduces accumulation in salivary gland tissue mitigating dose-limiting severe dry mouth side effects.